Waterloo, Belgium

Paul Croisier


Average Co-Inventor Count = 1.5

ph-index = 1

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 1976-1978

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Paul Croisier: Innovator in Memory Disorder Treatments

Introduction

Paul Croisier, based in Waterloo, Belgium, is a prominent inventor known for his contributions to the pharmaceutical field. With a total of three patents to his name, Croisier is actively engaged in developing novel compounds aimed at treating memory disorders. His work emphasizes the significance of innovative approaches in addressing complex health issues.

Latest Patents

One of Croisier's latest patents is focused on 2-Carbamoyl-1,2,4,5-tetrahydro-3H-2-benzazepin-3-ones. This invention involves new physiologically active compounds that hold promise in the treatment of memory disorders. The compounds feature a specific structural formula and various substituents that enhance their therapeutic potential. Another notable patent from Croisier is for 1,2,4,5-Tetrahydro-3H-2-benzazepin-3-ones, which are also designed for treating memory disorders, highlighting the pharmacological utility of these innovative compounds.

Career Highlights

Currently, Paul Croisier is associated with UCB Société Anonyme, where he collaborates with other researchers to further develop these groundbreaking inventions. His career is marked by a dedication to enhancing therapeutic options through innovative chemical compounds.

Collaborations

Croisier frequently collaborates with colleagues such as Ludovic Rodriquez and Ludovic Rodriguez. These partnerships play a crucial role in advancing their collective research efforts and contribute to the overall success of their projects in the pharmaceutical domain.

Conclusion

In summary, Paul Croisier stands out as an inventor whose work is pivotal in the development of medications aimed at memory disorders. His recent patents exhibit the potential for significant advancements in treatment, reflecting his commitment to innovation in healthcare. As Croisier continues his work at UCB Société Anonyme, the impact of his contributions will likely resonate in the medical field for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…